Pharming Group N.V. (AMS:PHARM)

Market Cap	498.33M
Revenue (ttm)	287.07M
Net Income (ttm)	-10.65M
Shares Out	680.31M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,458,088
Average Volume	9,534,308
Open	0.7400
Previous Close	0.7465
Day's Range	0.7270 - 0.7425
52-Week Range	0.6475 - 1.0270
Beta	0.64
RSI	36.35
Earnings Date	Mar 13, 2025

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-1...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 382
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: PHARM

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.03 million, 4.54% more than in 2023.

Financial numbers in USD